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Rationale: Diffusing capacity of the lung for carbon monoxide (DLCO) is a good marker of
disease severity in patients with idiopathic interstitial pneumonia (IIP). The combined diffusing
capacity of nitric oxide (DLNO) and DLCO determines the two components of diffusion:
membrane conductance (Dm, CO) and pulmonary capillary blood volume (Vc).
Objectives: The aim of this study was to evaluate Vc and Dm, CO in patients with fibrosing IIP in
order to determine the relative contribution of membrane resistance and vascular resistance
to the loss of DLCO.
Methods: 32 patients with IIP (IPF: n Z 22, NSIP: n Z 10) were evaluated using MRC dyspnea
scale, plethysmography, combined DLNO/DLCO, 6-min walk test (6 MWT), echocardiography
and chest computed tomography (chest CT).
Results: DLCO (41.8  11.9%pred), Dm, CO (40.5  12.7%pred) and Vc (41.9  18%pred) were
severely and equally reduced. Dm, CO and Vc were related to MRC scale, FVC, maximal desa-
turation during 6 MWT, and systolic pulmonary artery pressure (sPAP). There was no correlation
with the extent of fibrotic changes on chest CT.
Conclusions: Our main results indicate that Dm, CO and Vc contribute almost equally to DLCO
reduction in IIP. Dm, CO and Vc are related to functional indicators of disease severity and to
sPAP in agreement with the concept of vascular involvement in IIP.
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Lung capillary blood volume and membrane diffusion 565Introduction (Jaeger-Masterlab plethysmograph). The reference valuesIdiopathic pulmonary fibrosis (IPF) and non-specific inter-
stitial pneumonia (NSIP) are two idiopathic interstitial
pneumonias (IIP) of unknown etiology and poor prognosis.1
The pathogenesis of lung fibrosis is not clearly understood,
but alveolar epithelial cell injury, dysregulation of fibro-
blasts, vascular injury and aberrant angiogenesis related to
vascular remodeling are key elements.2
Diffusing capacity of the lung for carbonmonoxide (DLCO)
is a simple test which evaluates the efficiency of pulmonary
gas exchange. It is a valuable tool in the assessment of
pulmonary diseases and particularly IPF.3 Alteration of DLCO
may result from changes in gas exchange area, alveolar
capillary membrane thickness and ventilation/perfusion
relationship in the lung. Since the pulmonary capillary bed
also takes part in the gas exchange area, DLCO may also
reflect involvement of pulmonary capillaries.
According to the model of Roughton and Forster, DLCO is
composedof two resistancesarranged in series: [1/DLCOZ1/
Dm, CO þ 1/(qCo xVc)].4 Pulmonary membrane diffusing
capacity (Dm) for carbon monoxide (Dm, CO) is the CO
conductance across the alveolar-capillary tissue membrane
andplasmabarrier;qCO is the rateofcarbonmonoxideuptake
bywholebloodand combinationwithHbmeasured in vitro;Vc
is the pulmonary capillary blood volume. Themeasurement of
diffusingcapacityof the lungusing the transfergasnitricoxide
(NO) and CO together permits to obtain Dm, CO and Vc in
a single-breath experiment.5e7
The aim of this study was first to measure Vc and Dm, CO
in patients with fibrosing IIP in order to determine the
relative contribution of membrane resistance and vascular
resistance in the loss of DLCO and secondly to study their
relations with pulmonary function tests, chest computed
tomography (chest CT) and echocardiography.
Patients and methods
Thirty two patients with IIP were included in this prospec-
tive study. Inclusion criteria consisted of diagnosis of IPF
according to the American Thoracic Society/European
Respiratory Society guidelines and/or histopathological
evidence for usual interstitial pneumonia, or diagnosis of
NSIP (radiographic or histopathological diagnosis). Patients
were not included if they had another pulmonary disease
(including obstructive disease), left heart failure or
a history of pulmonary embolism. Connective tissue
diseases were ruled out. No acute exacerbation was
observed in the three months preceding inclusion. All
patients completed pulmonary function tests. Twenty
seven patients completed a modified MRC dyspnea scale.
An informed consent was obtained from all patients and
approval for the use of these data was provided by the
Institutional Review Board of the French learned society for
respiratory medicine.
Pulmonary function tests
Resting pulmonary function tests included measurement of
lung volumes by plethysmography and single breath diffu-
sion capacity of the lung for carbon monoxide (DLCO)used were those of the Official Statement of the European
Respiratory Society.8,9 A 6-min walking test was performed
according to ATS guidelines.10
DLNO and DLCO
DLNO and DLCO were measured simultaneously during
a single breath manœuvre using an automatic apparatus
(Medisoft Dinant, Belgium) as described by Aguilaniu
et al.11 The measurements of DLNO/DLCO were accepted if
two successive measurements of DLNO and DLCO gave
figures within 10%, otherwise a third measurement was
performed. Values of Dm, CO and Vc were calculated
according to the model of Gue´nard et al.7 1/qNO was
assumed negligible, therefore DLNO Z Dm, NO. Dm, CO
was calculated as Dm, NO/a where a Z 1.97 following
Graham’s law. To calculate Vc, qCO reference from
Roughton and Forster was chosen.4 Hemoglobin concen-
tration was not measured but set at 13.5 g/dL for women
and 14.5 g/dL for men. qCO values were multiplied by 13.5/
14.9 and 14.5/14.9 respectively. Reference values for
DLNO, Dm, CO and Vc used were those established by
Aguilaniu et al.11
Transthoracic echocardiography
A transthoracic echocardiography was performed at rest,
with the patient lying on the left side. Resting measure-
ments included left ventricular diameter and volume as
well as left ventricular ejection fraction using the biplane
Simpson method. Characteristic of the right ventricle (RV)
was also assessed namely, the RV end-diastolic diameter
and shortening fraction, tricuspid annular plane systolic
excursion (TAPSE), and tricuspid S-waves on Doppler
tissue imaging also provided an appreciation of the RV
systolic function. We also analysed pulmonary accelera-
tion time, the right ventricular-right atrium gradient on
continuous Doppler scans by analysis TR flow, subaortic
time-velocity integral of flow and inferior vena cava
collapsibility to estimate pressure in the RA. Systolic
pulmonary arterial pressure (sPAP) is considered equal to
right ventricular systolic pressure in the absence of
pulmonary valve stenosis. Right ventricular systolic pres-
sure, and so sPAP can be estimated using continuous wave
Doppler.
Chest computed tomography
Chest CT examinations were reviewed by two experienced
radiologists unaware of lung function data. Scans were
evaluated using a thin section CT (HRCT) scoring system for
lung fibrosis, based on ground glass attenuation (HRCT
alveolar score) and fibrotic change (HRCT interstitial score)
previously described.12,13
Statistical analysis
Results are presented as mean  SD. Following ATS/ERS
2005 guidelines, the lower limits of normal (LLN) were set
at the level of 5th percentile (or mean minus 1.645 RSD) of
Table 1 Characteristics of the 32 patients.
Mean  SD % Predicted
Age (years)a 63.1  10.4
Sex ratio (M/F) 25/7
height (m)a 1.7  0.08
Weight (kg)a 83.2  16
MRC (/4)e 1.4  1
FVC (L)a 2.73  0.76 75.7  17.1
FEV 1 (L)a 2.15  0.56 75.5  16.6
TLC (L) d 4.28  0.87 69  11.6
566 L. We´meau-Stervinou et al.each reference population.14 Results were conventionally
expressed as percent predicted. All statistical analysis were
carried out with GraphPad Prism 4.0 software (San Diego,
California, USA). Correlations were analysed using Spear-
man’s rank correlation test: three variables were tested
(DLCO, Vc and Dm, CO). For each variable a correlation
with FVC, minimal saturation during 6 MWT, sPAP and MRC
was studied. Four tests being performed with each vari-
able, a Bonferroni correction was performed to limit type I
errors. The corresponding level of significance is thus set to
0.0125 (0.05/4).DLCO 10 s (mL/min/mmHg)a 10.7  3.35 41.8  11.9
DLCO/VA (mL/min/mmHg/L)a 2.9  0.76 71.4  16.2
6 MWT : distance (m)b 391.8  108.1
6 MWT : minimal
saturation (%)b
87.4  5
sPAP (mmHg)c 33.8  8.3
DLCO 4 s (mL/mmHg/min)a 10  3.6 40.3  15.1
DLNO (mL/mmHg/min)a 56.9  18.33 40.5  12.7
Dm, CO (mL/mmHg/min)a 28.9  9.3 40.5  12.7
Vc (mL)a 27.5  10.78 41.9  18
MRC: Medical Research Council dyspnea scale; DLCO: Diffusing
capacity of the lung for carbon monoxide; Vc: capillary blood
volume; Dm, CO: membrane conductance for carbon monoxide;
6 MWT: 6 min walk test; sPAP: systolic pulmonary arterial
pressure.
a : n Z 32.
b : n Z 31.
c : n Z 30.
d : n Z 28.
e : n Z 27.Results
Characteristics of the population are summarized in
Table 1. The overall population consisted of 25 men and 7
women with a mean age of 63.1  10.4 years. Twenty two
patients had a diagnosis of IPF and 10 of NSIP. Diagnosis
was obtained by open lung biopsy in 8 cases. At the
time of inclusion in the study, 9 patients received
steroids, 2 patient received azathioprine, 3 patients
received mycophenolate mofetil, 1 patient received
methotrexate, 11 were included in therapeutic trials and
10 were untreated.
Pulmonary function tests and echocardiography
Results of pulmonary function tests are summarized in
Table 1: 25 of the 28 patients who underwent plethys-
mography demonstrated a restriction (TLC < LLN). DLCO
was below LLN for all patients. Sixteen of the 31 (51,6%)
patients who underwent 6 MWT had a minimal SpO2 below
88%.
Analysis of DLCO-DLNO showed that DLCO, Dm, CO and
Vc were equally reduced (Table 1). DmCO and Vc were
highly correlated (r Z 0.72 p < 0.0001) with few discrep-
ancies between their respective levels of impairment
(Fig. 1).
Results of echocardiography are summarized in Table 1.
Eleven of the 30 (36,6%) patients who underwent echocar-
diography had an estimated sPAP higher than 35 mmHg.
Chest computed tomography
Thirty two chest CT examinations were reviewed in total:
17 scans were reviewed on films, and the rest interpreted
on CD-ROM. Eighteen scans were reviewed using 5 mm cuts,
1 using 3 mm cuts, one using 7 mm cuts and 10 using 1 mm
cuts, though 1 mm cuts every 10 mm (old HRCT protocol)
were reviewed in each case. Thirteen studies were per-
formed using intravenous contrast medium.
An overall average ground glass score of 2.31 and an
interstitial score of 1.69 were obtained for the group of
patients studied. The highest ground glass and interstitial
scores were noted in the lower lobes with the lowest
scores in the upper lobes, as could be expected, given the
cases involved patients with diagnoses of IPF and NSIP.
The left lung values overall, were greater than those for
the right lung, concerning both ground glass and inter-
stitial elements; left lower lobe interstitial changeaverage score was slightly greater than that for the right
lower lobe.
Correlations between Vc, Dm, CO and studied
parameters
Correlations are illustrated by Figs. 2e4. DLCO, Dm, CO and
Vc were related to FVC (respectively r Z 0.63 p Z 0.0001;
r Z 0.56 p Z 0.0008; and r Z 0.56 p Z 0,0008). DLCO
expressed as percent of predicted values (DLCO%), Dm, CO
% and Vc% were also related to FVC% (Fig. 2). DLCO, Dm, CO
and Vc were related to the MRC score (respectively
r Z 0.47 p Z 0.01; r Z 0.45 p Z 0.01 and r Z 0.59
p Z 0.008).
DLCO was related to the 6 MWT minimal SpO2. So were
Dm, CO and Vc (Fig. 3). Lastly, DLCO was related to sPAP
and the same relation was found with Dm, CO and Vc
(Fig. 4).
No relations were observed between DLCO, Dm, CO, Vc
and CT scores, neither with ground glass score nor with
interstitial score.
Discussion
To our knowledge, this is the first study evaluating the
clinical relevance of combined DLCO/DLNO method in
patients with IIP. There were three main findings: 1/Dm, CO
and Vc contribute almost equally to DLCO reduction in IIP;
2/Dm, CO and Vc are related to several pulmonary










































Figure 1 A: Relationship between Dm, CO and Vc B: Relationship between Dm, CO and Vc expressed as percent of predicted
values Vc: capillary blood volume Dm (Dm, CO): Membrane conductance for carbon monoxide r: Spearman coefficient.
Lung capillary blood volume and membrane diffusion 567functional tests parameters; 3/Both Dm, CO and Vc are
correlated to sPAP.Dm, CO and Vc contribute almost equally to DLCO
reduction in IIP and are related to functional
indicators of disease severity
In our population, DLCO, Vc and Dm, CO were severely
and equally reduced. In patients with IIP, reduction of
DLCO may result from changes in gas exchange area,
barrier thickness and ventilation/perfusion mismatching
of the lung. Reduction of Vc may be caused by destruc-
tion, obstruction or compression of capillaries. Those
mechanisms are observed in fibrotic lung: capillary
density is decreased in the most extensively fibrotic
regions15; small clots were detected in the alveolar
capillary bed in lungs of patients who died after an acute
exacerbation.16 Reduction of Dm may be caused by
destruction, thickening or infiltration of the membrane.
The extent of these changes increases with disease
progression. It is therefore interesting to note that both
Dm, CO and Vc are correlated with classical functional
indicators of disease severity and progression lung
volumes measured by plethysmography (FVC), maximal
distance and minimal saturation of 6 MWT, MRC dypnea
scale; but not with chest CT fibrotic scores.
In normal subjects, vascular and membrane resistance
are both responsible for the global resistance to CO
uptake.17 In our study, we tried to determine whether the
membrane resistance or the vascular resistance accounted
for the loss of DLCO. Clearly, it shows that both the vascular
component and the membrane component are severely and
equally reduced: the disruption in the membrane and the
reduction of capillary blood volume contribute equally to
the abnormal diffusing capacity in IIP.
To our knowledge, this is the only study in interstitial
lung disease (ILD) to suggest these components are
affected equally. Other studies in various forms of ILD
have demonstrated a consistent decrease in Dm, CO with
relative preservation of Vc. In a previous study using the
Roughton and Forster method in patients with pulmonary
sarcoidosis, the authors have shown that Dm, CO was the
major determinant of impaired DLCO.18 Overbeek et al has
shown that the Dm, CO component was the principalcontributor to the reduction in DLCO in systemic sclerosis
with or without Pulmonary Arterial Hypertension (PAH).19
In the study by Van der Lee et al, DLCO was found to be
65% of predicted value, Vc 63% and Dm 53%, in diffuse
parenchymal lung disease of various aetiologies, suggest-
ing that Dm, CO was again the major determinant of DLCO
reduction.20 Our finding is of importance because we only
included patients with IPF or NSIP. This result suggests that
the vascular component is more affected in IIP that in
other ILD. In IPF, the degree of ventilation/perfusion
mismatch is greater than it is seen in other fibrotic lung
diseases, even after adjusting for disease severity.21 This
could be explained by heterogeneity of interstitial micro-
vascularity reported in IPF with vascular regression in sites
of active fibrosis and increased vessel density in areas of
mild interstitial change.15,22 This heterogeneity, paired
with anastomoses between the pulmonary and systemic
circulation23 could lead to shunting of blood away from
areas of gas exchange and thus to ventilation/perfusion
mismatch.
This result could also suggest that in IPF, Vc and Dm, CO
are dependent. This idea could be illustrated by the high
correlation found between the two components in our
study. Some investigations in patients with IPF show that
capillary density is significantly decreased in diseased
areas, leading to a decrease in the Vc component of the
DLCO in addition to the already lowered Dm, CO compo-
nent as a consequence of the diseased-thickened
membranes, thus making the Vc component dependent
on the Dm, CO component. Besides, hypoxemia due to
thickened membranes can lead to pulmonary vasocon-
striction. Moreover, the decrease of Vc will result in
a reduction in surface area available for gas exchange and
therefore in a decrease of Dm.24 NO diffusion might also
be impaired by ventilation heterogeneity, a known
mechanism of diffusion limitation.25 If Dm, CO and Vc are
dependent, the separation of the DLCO in these two
components becomes clinically irrelevant. Nevertheless,
since Dm, CO and Vc can be affected in different ways in
various diseases, their parallel impairment in IPF/NSIP
remains interesting. Another area of uncertainty
regarding the DLNO technique is the value of qNO. A
recent study by Borland et al. suggests that blood
conductance for NO might not be infinite, due to limiting
factors of erythrocytes.26







































Figure 2 Relationship between FVC and DLCO (A), Dm, CO
(B) or Vc (C). FVC, DLCO, Dm, CO and Vc are expressed as
percent of predicted values. FVC: Forced Vital capacity. FEV1:
Forced expiratory volume in 1 s. DLCO: Diffusing capacity of
the lung for carbon monoxide. Vc: capillary blood volume. Dm
(Dm, CO): Membrane conductance for carbon monoxide. r:
Spearman coefficient.















































































































Figure 3 Relationship between minimal saturation during
6 min walking test and DLCO (A), Dm, CO (B) or Vc (C). 6 MWT: 6
walk test. DLCO: Diffusing capacity of the lung for carbon
monoxide. Vc: capillary blood volume. Dm (Dm, CO):
Membrane conductance for carbon monoxide. r: Spearman
coefficient.
568 L. We´meau-Stervinou et al.Dm, CO and Vc are correlated with sPAP
Pulmonary hypertension (PH) is a severe complication of
IIP, associated with a poor prognostis.27,28 Significant PH is
more frequent when underlying fibrosis is severe, but may
occur at any stage of the disease process.27,29 In our study,
we estimated the sPAP values by transthoracic echocardi-
ography coupled with Doppler, which is a non-invasive
technique. sPAP estimated this way correlated well with
the values measured in patients with right cardiac catheter
studies.30 However, we must point out that some authors
reported various ranges of discordant results betweenechocardiography and right heart catheterisation.31 Care
must be taken to align the Doppler beam with the direction
of the flow or underestimation of the pulmonary artery
pressure may result. With these caveats, Doppler echo-
cardiography is a convenient, non-invasive, and relatively
accurate tool for the evaluation of PH.32
In IPF, DLCO is lower in patients with PH on right heart
catheterisation.27 Hamada showed a negative correlation
between DLCO (expressed in % of predicted values) and
mPAP.33 In our study we found this correlation between
DLCO and sPAP. However, Nathan et al. demonstrate that
DLCO levels measured in isolation are not reliably indicative
AB
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Figure 4 Relationship between sPAP and DLCO (A), Dm, CO
(B) and Vc (C) DLCO: Diffusing capacity of the lung for carbon
monoxide Vc: capillary blood volume Dm (Dm, CO): Membrane
conductance for carbon monoxide sPAP: Systolic pulmonary
arterial pressure r: Spearman coefficient.
Lung capillary blood volume and membrane diffusion 569of PH.29 In our study, sPAP correlated inversely with Vc and
Dm, CO. Relations between hemodynamic values and the
vascular component of DLCO have been previously re-
ported: Oppenheimer et al. showed an inverse relationship
between mPAP and Vc in a group with miscellaneous forms
of PH, whereas they did not find the correlation between
Dm, CO and mPAP.34 Others found no relationship between
hemodynamic parameters of pulmonary hypertension and
Dm, CO or Vc in systemic sclerosis.19 Borland et al. found
that Vc was lower in patients with severe unexplained
pulmonary hypertension than in normal subjects.35 Another
study, considering patients with various infiltrative lungdisease (connective tissue disease, asbestosis, sarcoidosis
or unknown origin) showed that Vc, determined by the
Roughton and Forster method was paradoxically often high,
almost normal in patients with chronic infiltrative lung
disease and PH.5,36 To our knowledge, the present study is
the first to demonstrate a relationship between sPAP and
both Dm, CO and Vc in fibrosing IIP.
The recent data from clinical studies suggest that the
predominent mechanisms for the development of PH in IPF
may not be hypoxic vasoconstriction and pulmonary capil-
lary loss. The presence of PH cannot be explained in all
patients by hypoxemia or degree of lung function reduc-
tion.28,37 It seems likely that the biological processes
underlying fibrosis progression are also involved in the
vascular remodeling and PH.38 The histopathologic changes
in pulmonary arteries of UIP lungs show thickening of the
smooth muscle layer, proliferative intima lesions and
complete occlusion of the vessel by scar tissue and plexi-
form lesions.39 It is therefore not surprising that both the
membrane and the vascular resistance are related to the
increase of sPAP.
In conclusion, our results demonstrate that alterations of
Dm, CO and Vc contribute equally to reduction of DLCO in
patients with IIP. They are both related to severity of lung
involvement and to the development of increased pulmonary
arterial pressure. Due to the parallel impairment of
membrane and vascular component in IIP, DLCO-DLNO
appears at present to add little in the routine assessment
of these disorders, clinical correlates being in addition
similar for DLCO, Dm and Vc. However the relevance of
DLNO/DLCO to evaluate new therapeutic interventions tar-
geting the vascular component should be studied.
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